News | Magnetic Resonance Imaging (MRI) | November 12, 2020

GE's SIGNA 7.0T Receives FDA Clearance

GE Healthcare announced U.S. FDA 510(k) clearance of SIGNA 7.0T magnetic resonance imaging (MRI) scanner. With a magnet approximately five times more powerful than most clinical systems, SIGNA 7.0T can image anatomy, function, metabolism and microvasculature in the brain and joints with incredible resolution and detail.

November 12, 2020 — GE Healthcare announced U.S. FDA 510(k) clearance of its SIGNA 7.0T magnetic resonance imaging (MRI) scanner. With a magnet approximately five times more powerful than most clinical systems, SIGNA 7.0T can image anatomy, function, metabolism and microvasculature in the brain and joints with incredible resolution and detail. This new system can be used for both research and clinical purposes to support a broad range of investigations across neurologic and musculoskeletal diseases.  

With a powerful 7.0 tesla magnet at its core, SIGNA 7.0T combines a broad range of advanced technology, imaging methods, and years of GE Healthcare experience into a new imaging tool. The completely new SIGNA 7.0T features UltraG gradient technology, GE’s most powerful whole-body gradient coil, to meet the demands of ultra-high field imaging speed and resolution, advanced diffusion, and functional brain imaging.

This system also features GE’s latest SIGNAWorks software platform with state-of-the-art applications such as deep learning-based tools like AIR x brain for automated slice positioning and Silent MR imaging, enabling seamless protocol translation between GE MR systems. In addition, SIGNA 7.0T is equipped with Precision RF transmit and receive architecture to enable improved image quality and enable development in parallel transmit. This system also provides a unique platform for advanced knee and cartilage imaging, allowing for ultra-high-resolution anatomical visualization as well as research capabilities to measure quantitative changes in anatomy due to disease.

“We are thrilled to add SIGNA 7.0T to our portfolio,” said Jie Xue, president and CEO of GE Healthcare MR. “This new scanner is a critical tool in research for neurological disorders like Alzheimer’s disease and mild traumatic brain injury. Now clinicians will have access to the power of ultra-high field imaging combined with the ultra-high-performance gradients to translate research advances into new clinical diagnostic tools and potential treatment options.”

For more information: www.gehealthcare.com

 

Related 7T content:

FDA Clears First 7T MRI System, Magnetom Terra

 

Related Content

Guerbet announced the launch of OptiProtect 3S, a new range of technical services for its injection solutions. OptiProtect 3S is designed to support imaging centers in the daily use and protection of their injection solutions.
News | Contrast Media Injectors | February 25, 2021
February 25, 2021 — Guerbet announced the launch of ...
Advanced technologies and applications such as point-of-care, pediatrics, dry-magnets, compact MRI and fusion imaging are driving global market
News | Magnetic Resonance Imaging (MRI) | February 24, 2021
February 24, 2021 — Frost & Sullivan's recent analysis, Technological Advancements and Emerging Applications in t
55-year-old woman who underwent screening mammogram and ultrasound 7 days after first COVID-19 vaccination dose. Screening mammogram and US demonstrated unilateral left axillary lymph node with cortical thickness of 5 mm on ultrasound (not shown). BI-RADS category 0 was assigned. Ultrasound from diagnostic work-up performed 7 days later showed no change in lymph node size. BI-RADS 3 was assigned. #COVIDvaccine #COVID19

55-year-old woman who underwent screening mammogram and ultrasound 7 days after first COVID-19 vaccination dose. Screening mammogram and US demonstrated unilateral left axillary lymph node with cortical thickness of 5 mm on ultrasound (not shown). BI-RADS category 0 was assigned. Ultrasound from diagnostic work-up performed 7 days later showed no change in lymph node size. BI-RADS 3 was assigned.

News | Breast Imaging | February 24, 2021
Detroit-based magnetic resonance imaging (MRI) technology company SpinTech, Inc. has acquired medical-imaging research and technology developer Magnetic Resonance Innovations, Inc. (MR Innovations).
News | Magnetic Resonance Imaging (MRI) | February 24, 2021
February 24, 2021 — Detroit-based magnetic resonance...
Findings indicate that PPC and GG are highly predictive of overall upstaging by PSMA PET/CT for patients with high-risk prostate cancer

Image courtesy of UCLA Health

News | PET-CT | February 23, 2021
February 23, 2021 — A...
Dr Sahar Saleem placing the mummy in the CT scanner

Dr. Sahar Saleem placing the mummy in the CT scanner. Image courtesy of Sahar Saleem

News | Computed Tomography (CT) | February 22, 2021
February 22, 2021 — Modern medical technology is helping scholars tell a more nuanced story about the fate of an anci
Examples of the imaging performance of XPCI-CT (b,e) compared to conventional specimen radiography (a,d) and benchmarked against histopathology (c,f). he top row focuses on the similarity between the XPCI-CT slice in (b) and the histological slice in (c). Arrow 1 indicates margin involvement, arrow 2 a variation in density in the internal structure of the tumour mass, arrow 3 tumour-induced inflammation. All this is confirmed by the histological slice in (c), and hardly visible in the conventional image in

Examples of the imaging performance of XPCI-CT (b,e) compared to conventional specimen radiography (a,d) and benchmarked against histopathology (c,f). he top row focuses on the similarity between the XPCI-CT slice in (b) and the histological slice in (c). Arrow 1 indicates margin involvement, arrow 2 a variation in density in the internal structure of the tumour mass, arrow 3 tumour-induced inflammation. All this is confirmed by the histological slice in (c), and hardly visible in the conventional image in (a). The bottom row focuses on the detection of small calcifications, a key feature in DCIS. These are undetectable in (d), detected in (e), enhanced in the maximum intensity projection (MIP) image at the bottom of (f), and confirmed by histopathology in the top part of (f). The scale bar [shown in (b) and (e)] is the same for all images apart from (f), which has its own scale. Red arrows in (e) and (f) indicate the microcalcifications. Image courtesy of Professor Alessandro Olivo

News | Breast Imaging | February 22, 2021
February 22, 2021 — A new X-ray imaging scanne
Axial FLAIR MR image shows T2 prolongation in bilateral middle cerebellar peduncles (arrows). Findings were associated with restricted diffusion and areas of T1 hypointense signal without enhancement or abnormal susceptibility. Image courtesy of American Roentgen Ray Society (ARRS), American Journal of Roentgenology (AJR)

Axial FLAIR MR image shows T2 prolongation in bilateral middle cerebellar peduncles (arrows). Findings were associated with restricted diffusion and areas of T1 hypointense signal without enhancement or abnormal susceptibility. Image courtesy of American Roentgen Ray Society (ARRS), American Journal of Roentgenology (AJR)

News | Coronavirus (COVID-19) | February 22, 2021
February 22, 2021 — According to an...